[6] DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012; 132:785.

[7] Kiprono SK, Chaula BM, Beltraminelli H. Histological review of skin cancers in African Albinos: a 10-year retrospective review. BMC Cancer 2014; 14:157.

SUMMARY

[016] The present disclosure is directed to a method of treatment and/or prevention of basal cell carcinoma lesions, comprising topically administering a pharmaceutical composition comprising patidegib or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, to a subject in need thereof, wherein the subject eligible for the treatment and/or prevention is selected according to any one of the following criteria (i) the subject must have at least 6 facial BCC lesions; or (ii) the subject must have a genetic mutation PTCH; or (iii) the subject must have at least 6 BCC lesions and a genetic mutation PTCH.

[016a] In an aspect, there is provided a use of patidegib or a pharmaceutically acceptable salt thereof, in the preparation of a topical medicament for the treatment and/or prevention of basal cell carcinoma lesions, in a subject in need thereof, wherein the subject must have a genetic mutation PTCH1 and suffers from Gorlin syndrome.

BRIEF DESCRIPTION OF THE DRAWINGS

[017] The subject matter regarded as the invention is particularly pointed out and distinctly claimed in the concluding portion of the specification. The invention, however, both as to organization and method of operation, together with objects, features, and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanying drawings in which:

[018] **Figure 1**: Graphic illustration of number of new basal cell carcinoma (BCCs) lesions excluding no longer suspicious BCCs, observed, for subject suffering from PTCH1 mutation. Based on the study described in Example 2.

[019] **Figure 2**: Graphic illustration of number of new BCCs excluding no longer suspicious BCCs, observed, for subject suffering from PTCH1 mutation and has at least 6 facial BCC lesions at baseline. Based on the study described in Example 2.

[020] **Figure 3**: Graphic illustration of number of new BCCs excluding no longer suspicious BCCs, observed, for subject suffering from PTCH1 mutation and has at least 8 facial BCC lesions at baseline. Based on the study described in Example 2.

[021] **Figure 4**: Graphic illustration of number of new BCCs excluding no longer suspicious BCCs, observed, for subject suffering from PTCH1 mutation and has at least 10 facial BCC lesions at baseline. Based on the study described in Example 2.